Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp
Links shared publicly online about this topic.
- 1,377total visits
Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp
fda.gov —
The FDA is requiring all drugs called Erythropoiesis-Stimulating Agents (ESAs) to be prescribed and used under a risk management program, known as a risk evaluation and mitigation strategy (REMS), to ensure the safe use of these drugs.
View full resource at fda.gov
Tags: Anemia Medication, Drug, FDA, Aranesp, Procrit, Epogen
Most Recently Shared on February 16, 2010 at 4:35 pm By:
RT @FDA_Drug_Info: Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp: http://bit.ly/9hCNtM
Advertisement
